Michael Banks, MD, announces the launch of the Multiple Myeloma Content Hub on The Doctor’s Channel. Check back soon for interviews with thought leaders in the space, case…
Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, discusses promising results from current clinical trials for newly diagnosed multiple myeloma. The GRIFFIN trial…
In an interview conducted during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute in…
In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL,…
Brian G. M. Durie, MD, chairman of the board of the International Myeloma Foundation, discusses whether patients with borderline high-risk smoldering myeloma should begin treatment early. Some treatments…
In a sequencing study of 82 patients with smoldering multiple myeloma, there were fewer NRAS and FAM46C mutations and with fewer adverse translocations – del(1p), del(14q), del(16q), and…
In a study of 16,331 patients in the California Cancer Registry, 5.7% developed a second primary malignancy more than 1 year after diagnosis. The 10-year cumulative incidence of…
